Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer
S Popat, Y Barbachano, S Ashley, A Norton, M O'Brien - Lung Cancer, 2008 - Elsevier
BACKGROUND: Both docetaxel and erlotinib improve overall survival over best supportive
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …
Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) …
R Ng, M Loreto, R Lee, NB Leighl - Lung Cancer, 2008 - Elsevier
BACKGROUND: Randomized trials of advanced non-small cell lung cancer (NSCLC) have
demonstrated the activity of docetaxel in second-line and erlotinib in the third-line setting …
demonstrated the activity of docetaxel in second-line and erlotinib in the third-line setting …
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …
JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung cancer, 2014 - Elsevier
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …
[PDF][PDF] Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - researchgate.net
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …
Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
B Melosky, J Agulnik, H Assi - Current Oncology, 2008 - mdpi.com
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
chemotherapy have both demonstrated efficacy in recurrent metastatic non-small-cell lung …
TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?
V Lorusso, N Silvestris, I Marech - … Journal of the American Society of …, 2012 - europepmc.org
A comment on this article appears in" Reply to V. Lorusso et al." J Clin Oncol. 2013 Jan 10;
31 (2): 289-9. This is a comment on" First-line erlotinib followed by second-line cisplatin …
31 (2): 289-9. This is a comment on" First-line erlotinib followed by second-line cisplatin …
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors
P Krawczyk, DM Kowalski, K Wojas-Krawczyk, R Mlak… - Chemotherapy, 2012 - karger.com
Background: We evaluated the effectiveness of docetaxel or erlotinib in second-line
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …
treatment of non-small cell lung cancer (NSCLC) and focused on the impact of predictive …
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
JW Neal - Future Oncology, 2010 - Future Medicine
The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …
A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 …
JG Aerts, H Codrington, S Burgers… - Annals of …, 2012 - annalsofoncology.org
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study
A Vergnenegre, EF Smit, E Toy, B Parente… - … medical research and …, 2012 - Taylor & Francis
Objectives: SELECTTION was a multinational, prospective observational study to assess the
choice of and the time from initiation of second-line treatment to treatment discontinuation for …
choice of and the time from initiation of second-line treatment to treatment discontinuation for …